Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05249569 · ClinicalTrials.gov registry record · Phase 2
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05249569: Clinical Trial Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
NCT05249569 is a Phase 2 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05249569, a Phase 2 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Across cancer types, immune checkpoint inhibitors have been shown to induce complete response, partial response, and stable disease after initial evidence of radiographic increase in tumor burden. Treatment beyond progression should be considered when the patient is stable (or improving) symptomatically and if tumor reassessment can be performed within a short period.
Primary Outcome
To determine the objective response rate of combination axitinib,avelumab, and bavituximab in advanced HCC not previously treated with systemic therapy.
Interventions
- DRUG Axitinib
- DRUG Avelumab
- DRUG Bavituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2022-12-30 |
| Phase | Phase 2 |
Why NCT05249569 stopped before completion
NCT05249569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Axitinib is the first listed.
NCT05249569 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05249569 about?
NCT05249569 is a clinical study titled "Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma". Across cancer types, immune checkpoint inhibitors have been shown to induce complete response, partial response, and stable disease after initial evidence of radiographic increase in tumor burden. Treatment beyond progression should be considered when the patient is stable (or improving) symptomatic...
What is the current status of trial NCT05249569?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-11-04. Estimated completion is 2022-12-30.
What interventions are being tested in trial NCT05249569?
The interventions under investigation include: Axitinib (DRUG), Avelumab (DRUG), Bavituximab (DRUG).
Who is sponsoring clinical trial NCT05249569?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05249569's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI